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Infectionconstitutesaseriousadverseeventinpatientssubmittedtodeepbrainstimulation,oftenleadingtoremovalofthedevice.
We set to evaluate the potential role of immunoscintigraphy with 99mTc-labelled antigranulocyte antibody fragments (99mTc-
sulesomab) in the management of infection following DBS. 99mTc-sulesomab immunoscintigraphy seems to correlate well with
the presence and extent of infection, thus contributing to diﬀerentiate between patients who should remove the hardware entirely
at presentation and those who could undergo a more conservative approach. Also, 99mTc-sulesomab immunoscintigraphy has a
role in determining the most appropriate timing for reimplantation. Finally, we propose an algorithm for the management of
infection following DBS surgery, based on the results of the 99mTc-sulesomab immunoscintigraphy.
1.Introduction
Deep brain stimulation (DBS) is an eﬀective treatment
option for a number of neurological disorders, including
movement disorders, pain, and epilepsy [1–4]. Following
DBS procedures, skin erosion and/or infection can occur,
most commonly at the connector site [5, 6]. Infection consti-
tutes a serious adverse event because it often leads to removal
of the DBS system, with consequent loss of the clinical ben-
eﬁts of stimulation. Also, from an economical perspective,
infection greatly adds to the costs of DBS treatment, as
this complication often requires hospitalization, prolonged
antibiotic therapy, and additional surgical procedures. Cur-
rently there are no guidelines that speciﬁcally address the
issue of hardware-related infection. In a pooled analysis of
ten studies concerning hardware-related complications of
DBS, which included 922 patients, hardware removal was
necessary in 80% of the patients who developed infections
[5]. Nevertheless, reports of successful conservative treat-
ment with antibiotics alone seem to indicate that removal
of the stimulation device is not always necessary and that
conservative treatment could be considered as ﬁrst choice in
cases of circumscribed extracranial hardware infections [7].
The evaluationof the true extentof the extracranial infection
can be troublesome in clinical practice and the decision
of which patients are candidates for a conservative medical
approach in contrast to immediate surgical treatment is
usually not suﬃciently clear-cut.
To address the issue of infection management follow-
ing DBS surgery, we set to evaluate the potential role
of immunoscintigraphy with 99mTc-labelled antigranulo-
cyte antibody fragments (sulesomab) in the development
of a rational therapeutic approach to infection in patients
with Parkinson’s disease (PD) submitted to DBS. 99mTc-
sulesomab consists of monoclonal murine IgG antibody Fab’
fragments labeled with technetium-99m that have aﬃnity
for a 42kDa glycoprotein found on the surface of activated
granulocytes (NCA-90 surface antigen). Immunoscintigra-
phy with 99mTc-sulesomab has been used in diﬀerent clinical2 Neurology Research International
settings to detect infectious foci, including bone and joint
infection, soft tissue infection, and in the investigation of
fever of unknown origin [8, 9]. There is currently no data
reporting its eﬃcacy in the context of DBS surgery.
2. Methods
This preliminary study involved eight consecutive PD pa-
tients with persistent device-related skin erosion and/or
infection. All patients had been previously submitted to DBS
of the subthalamic nuclei (STN) in a single center, in the
period between November 2002 and October 2008. Bilateral
electrode implantation in the STN was followed by impulse
generator (Kinetra, Medtronic Inc.) placement in an infra-
clavicular subcutaneous pouch, in a single-stage procedure
performed by the same team of surgeons. In addition, two
of the patients underwent routine IPG replacement surgery
in October 2008 and April 2009, respectively. Perioperative
intravenous antibiotic prophylaxis was administered to all
patients (vancomycin and ceftriaxone). After the surgery,
routine follow-up visits were scheduled at regular intervals
with a team of movement disorders specialists.
The detection of skin erosion and/or infection prompted
adequate treatment with antibiotics. In addition, some of
the patients underwent partial removal and/or replace-
ment of hardware components in an attempt to con-
trol infection. Because of persistent or recurrent wound
dehiscence, immunoscintigraphy with 99mTc-sulesomab was
subsequently performed between July 2009 and April 2010.
Planar scans and SPECT-CT were acquired 4h and 24h after
injection of 99mTc-sulesomab (Immunomedics Inc) using a
dual-head gamma camera coupled with a low-power X-ray
tube. Depending on the scan results, patients were further
subjected to wound debridement alone or in combination
with either partial or complete hardware removal. Microbio-
logicalexaminationswereperformedfromtheskinexudates,
when available. At followup, three patients repeated the scan
in order to determine the feasibility of reimplantation of the
stimulation hardware. Medical records of all patients were
reviewed and data collected retrospectively.
3. Results
Patients’ characteristics, including the location of skin ero-
sion and/or infection and the results of any surgical reinter-
ventionsprecedingtheimmunoscintigraphy,aredescribedin
Table 1. The results of the 99mTc-sulesomab immunoscintig-
raphy and the subsequent therapeutic procedures are sum-
marized in Table 2,a sw e l la sp a t i e n to u t c o m ea n df o l l o w u p .
3.1. Location of Skin Erosion and/or Infection. Of the six
patients who developed hardware-related erosion and/or
infection after the initial DBS surgery, ﬁve patients presented
with wound dehiscence of the retroauricular incision, which
in most cases occurred in isolation (patients 2–4). In the
remainder of cases, the retroauricular wound dehiscence
occurred in association with dehiscence at distinct locations,
namely,theleftfrontalincision(patient1)andtheskinalong
the extension cables pathway in the neck (patient 5). One
patient presented with isolated left frontal wound dehiscence
(patient 6). Two additional patients presented with subclav-
icular wound dehiscence that developed after routine IPG
replacement due to end of battery life. Patient 7 initially
developed a hematoma at the IPG implantation site that was
surgically addressed before persistent infection developed.
In addition, patient 8 subsequently presented with wound
dehiscence of the left frontal incision. Staphylococcus aureus
was isolated from the wound exudate in most cases.
3.2. Pattern and Location of Tracer Uptake. In most patients,
the results of the immunoscintigraphy matched the exact
location of the wound dehiscence, with a focal pattern of
uptakeunderlyingtheareaofskininfection(Figures1(a)and
1(b)). Nonetheless, a few exceptions are worth mentioning
in greater detail. Firstly, both patients 1 and 5 showed an
increased tracer uptake that was more diﬀuse than could be
expected from clinical inspection of the wounds; speciﬁcally,
these patients’ scans showed a diﬀuse tracer uptake that
included the frontal areas, albeit the absence of clinical signs
of infection at these locations (Figure 1(c)). The presence
of infection at these clinically unapparent locations was
conﬁrmed during surgery. As described in the following
paragraph, these ﬁndings have had an impact on subsequent
treatment strategies. Another exception was patient 4, whose
scan did not show areas of increased uptake; of relevance,
this was the only documented case with a negative microbi-
ological examination of the wound serous exudate. Finally,
patient 8 had unexpected intracranial uptake of the tracer
(Figure 1(d)), which also inﬂuenced the course of treatment
decisively.
3.3. Therapeutic Approach according to 99mTc-Sulesomab
Immunoscintigraphy.
3.3.1. Frontal or Diﬀuse Tracer Uptake. The two patients who
presented with a diﬀu s et r a c e ru p t a k e( p a t i e n t s1a n d5 )
underwent a complete removal of the stimulation system,
and with this approach the skin infections healed properly.
It should be mentioned that both these patients had already
undergonesurgicalr emo valofextracranialDBSc omponents
(IPGandextensioncables)priortotheimmunoscintigraphy,
a procedure that had been ineﬀective. Therefore, in both
patientswithdiﬀusetraceruptakeatmultiplelocationsalong
the trajectory of extracranial hardware components, only
complete removal of the stimulation system was eﬀective in
treating the hardware-related infection.
Patient 6 had an abnormal focal tracer uptake in the left
frontal area (corresponding to the burr hole site), and partial
removalofthestimulationsystemincludingtheleftelectrode
was performed; the decision to remove the electrode was
based on the fact that it was in direct contact with the pus,
as could be observed during surgery. Although the right
electrode was initially spared, it was later removed due to
persistence of infection. Of note, the right electrode followed
an extracranial trajectory to the left and was thus under the
area of the original infection.Neurology Research International 3
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S S
PR RA
A
1.94 1.94 1.94 × × ×
(a)
LL P
P
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1.44 1.44 1.44
1059.60 57.99 66.82 −
×× ×
(b)
(c)
LL L R R R
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(d)
Figure 1: 99mTc-sulesomab immunoscintigraphy (SPECT/CT fusion images). (a) Three plane images of Patient 2, showing focal tracer
uptake restricted to the subcutaneous left temporal area, corresponding to the connector site. (b) Three plane images of Patient 7, showing
left chest wall focal tracer uptake, in the area corresponding to the IPG pouch. (c) Axial and coronal images of Patient 1, showing diﬀuse
tracer uptake along the extracranial trajectory of the right electrode. (d) Coronal images of Patient 8, showing left frontal and intracranial
focal areas of tracer uptake, along the path of the electrodes.
Because patient 8 presented with intracranial tracer
uptake, a complete removal of the stimulation system
was undertaken, even though the patient had no clinical
symptoms or signs of encephalitis, and cranial CT could
not demonstrate areas of contrast enhancement suggestive of
intracranial infection.
3.3.2. Focal Retroauricular or Subclavicular Tracer Uptake.
Patients 2 and 3 initially underwent a more conservative
surgical approach, owing to the fact that wound dehiscence
and tracer uptake were both localized to the retroauricular
incision. Wound debridement was the treatment option for
patient 2, based on the fact that no purulent exudate could
be identiﬁed during surgery—performed after prolonged
antibiotic therapy—despite the presence of tracer uptake at
that location. Afterwards, due to recurrence of infection,
IPG and extension cables were removed. Patient 3 had
previously removed the IPG and extension cables and also6 Neurology Research International
underwent wound debridement, in addition to removal of
the electrode protective caps, which contained a purulent
exudate.However,duetopersistenceofinfection,thispatient
later underwent bilateral electrode removal.
The only patient with isolated subclavicular wound
dehiscence (patient 7) had a focal tracer uptake on the chest
wallandunderwentremovaloftheIPGandextensioncables,
which proved to be a successful strategy.
3.3.3. No Tracer Uptake. Finally, the only patient with a
negative scan (patient 4) underwent wound debridement
alone.Later,duetopersistentskinerosion,intheabsenceofa
purulent drainage or positive cultures, contralateral transpo-
sition of the extracranial DBS components was performed.
3.4. Follow-Up 99mTc-Sulesomab Immunoscintigraphy and
Reimplantation Surgery. Patients 2, 3, and 5 repeated the
immunoscintigraphy scans in order to evaluate the feasibility
of a reimplantation surgery. The scans were repeated on
average three months after removal of DBS components.
While patient 2 had a normal scan and underwent reim-
plantation of the IPG device, patients 3 and 5 maintained
foci of increased 99mTc-labeled sulesomab uptake, and
reimplantation procedures were not attempted.
4. Discussion
Hardware infection in the context of DBS occurs at a rate of
approximately 1–15%, depending on the series [5]. It usually
representsamajormanagementconcern,oftenleadingtothe
loss of the stimulation device. Several studies have analyzed
the role of potential host risk factors in the development
of skin complications following DBS implantation and
failed to demonstrate a signiﬁcant association [6, 10–13].
Nevertheless, because the rate of skin complications is higher
in patients with PD than in patients with other diagnoses,
it has been suggested that skin alterations in relation to PD
itself could contribute to the occurrence of this adverse event
[11, 12]. Also, a straight scalp incision and a period of exter-
nalization of the electrodes in dual-stage procedures have
been suggested to increase the infection rate [14], although
thelatterhasnotbeenconﬁrmedinotherstudies[10,12,13].
The utilization of Kinetra devices has also been implicated
as a risk factor for the development of skin complications,
due to its larger volume when compared to other types
of IPG [11, 13]. Strategies to reduce the incidence of this
complication have focused mainly on the development of
smaller hardware components, reduction of operative times,
and avoidance of temporary electrode externalization. It
has also been suggested that local antibiotic application in
addition to intravenous prophylaxis could lower the rate
of infection after deep brain stimulator implantation [15].
While our knowledge on what factors associate with the
development of skin complications does not progress to
the point they can be prevented, it is important to focus
on strategies that help clinicians decide the best treatment
approach for each individual patient. Several authors con-
sider that a conservative treatment trial with antibiotics may
be warranted in certain cases [7, 14] while others ﬁnd an
early surgical approach more appropriate [13]. Nevertheless,
the management of skin complications following DBS is still
controversial, and no speciﬁc guidelines have been issued.
In most published series, infection is ﬁnally treated
with complete hardware removal, despite initial attempts at
more localized treatment. The major issue about infection
management is being able to identify which patients should
undergo hardware removal and to what extent. Diﬀerent
treatment algorithms have been published trying to address
this issue. The most consensual approach is that all hardware
components that are in direct contact with the infection
should be removed and that complete hardware removal
should be used in patients with disseminated or multiple
infectious foci [13, 16]. While generally agreeing with this
strategy, there are still a large proportion of patients who fail
the attempts to preserve the brain electrodes. Of relevance,
our immunoscintigraphy results demonstrate that infection
canbepresentinareasthatlookclinicallyintact(i.e.,without
skin erythema and swelling, erosion, or purulent discharge)
due to the subcutaneous dissemination of infection from
the primary site. In two of our patients, there was an
unexpected tracer uptake in the frontal areas, despite the
fact that the scalp wounds were clinically intact. These
ﬁndings led to a more aggressive treatment approach than
had initially been considered. Signiﬁcantly, infection at these
apparently intact locations was conﬁrmed during surgery by
the presence of pus. By allowing the accurate determination
of the subcutaneous extent of the infection, which may not
be clinically evident, 99mTc-sulesomab scans could indeed
inﬂuence the treatment strategy of post-DBS infection, with
ad i ﬀuse or frontal uptake indicating the necessity of a
complete removal of the stimulation system at presentation,
thus avoiding conservative strategies that will most likely fail,
inanunsuccessfulattempttopartiallypreservethehardware.
The same strategy must apply to patients with intracranial
tracer uptake (which was also an unexpected ﬁnding in our
series), who should undergo immediate removal of DBS
entirely.
In those cases of circumscribed infection with a focal
tracer uptake, hardware-related infection could potentially
be treated with a more conservative approach. In particular,
infections around the IPG or the extension cables could be
successfully treated with electrode preservation [13]. The
accurate determination of which hardware components are
in direct contact with the infection can be accomplished
during surgery, which explains the recommendation that the
surgical treatment of hardware infection should depend on
surgical ﬁndings [16]. But the fact that the 99mTc-sulesomab
immunoscintigraphy can help determine the actual extent
of the infection in the preoperative stage can turn out to
be very helpful in planning the surgical approach, as it
can demonstrate all areas of involvement by the infectious
process before the surgical procedure.
The results of a follow-up 99mTc-sulesomab immun-
oscintigraphy could also facilitate the decision of whether
and when a reimplantation procedure would be appropriate.
In other words, a normal follow-up scan can help identify
which patients are more likely to be safely reimplanted atNeurology Research International 7
Conservative surgery
(electrode sparing)
Reimplantation of DBS components
Negative follow-up 99mTc-sulesomab
immunoscintigraphy (performed at
least 3 months after removal of DBS)
Complete DBS removal
99mTc-sulesomab immunoscintigraphy
Frontal or diﬀuse uptake
Intracranial uptake
Focal retroauricular or
subclavicular uptake
Hardware-related infection
Figure 2: Proposed algorithm for the management of hardware-related infection.
a later time. In contrast, patients who persistently demon-
strate an abnormal uptake should not be considered for a
reimplantation procedure, as the risk of recurrent infection
is presumably high.
To our knowledge, there is no data reporting 99mTc-
sulesomab immunoscintigraphy eﬃcacy in the context of
DBS. Our ﬁndings indicate that the scintigraphy correlates
well with the presence of infection in this particular clinical
setting, since all patients with a positive bacterial culture of
the skin exudate had an abnormal scan, and the only patient
with a negative culture had a normal scan. Also, the location
of the foci of infection, as demonstrated by the presence of
pus during the surgical procedures, matched the location
of the tracer uptake, even in those cases with clinically
unapparent infection. This indicates that 99mTc-sulesomab
immunoscintigraphy is a reliable method to detect infection
in the context of DBS, thus contributing to the assessment of
patients with hardware-related infection. A ﬁnal statement
on the availability of the 99mTc-sulesomab immunoscintig-
raphy should be made—this imaging modality should be
available at every hospital that has access to nuclear medicine
imaging, speciﬁcally a SPECT-CT scanner. Although the
costsofthescintigraphyarestillconsiderable(approximately
850 US dollars), it is likely cost eﬀective. By allowing a better
distinction between patients who should have immediate
removal of the whole system and those who could undergo a
moreconservativeapproach,ithasthepotentialtoreducethe
number of hospital admissions, surgical interventions, and
prolonged antibiotic treatments that most patients endure
while attempting to preserve the stimulation device.
5. Conclusion
Although only preliminary data is available in a small
number of patients and more extensive followup is desirable,
99mTc-sulesomab immunoscintigraphy seems to correlate
well with the presence and extent of infection and therefore
has a potential role in the management of skin compli-
cations following DBS surgery. It is particularly helpful in
discriminating between patients who should remove DBS
entirely at presentation and those in whom a conservative
approach is more likely to succeed, thus complementing
clinical and surgical assessments. Also, 99mTc-sulesomab
immunoscintigraphy has the potential to be very useful in
thedeterminationofwhichpatientsshouldbeconsideredfor
reimplantation surgery. Finally, we propose an algorithm for
the management of infection following DBS, based on the
diﬀerent patterns of tracer uptake in the 99mTc-sulesomab
immunoscintigraphy (Figure 2).
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